tldrdailynews.com logo

Life Biosciences secures $80M to test aging-reversal gene therapy

1 min read
Source: Endpoints News
Life Biosciences secures $80M to test aging-reversal gene therapy
Photo: Endpoints News
TL;DR

David Sinclair’s Life Biosciences raised $80 million to move a one-time anti-aging gene therapy into clinical testing, pursuing partial epigenetic reprogramming with Yamanaka factors (Oct4, Sox2, Klf4) delivered by AAV to rewind cellular aging.

Topics:healthbiotech#anti-aging#biotech#david-sinclair#gene-therapy#life-biosciences#longevity
Share this article
  1. David Sinclair startup raises $80M for clinical test of anti-aging gene therapy  Endpoints News
  2. Can aging be reversed? First human trials set to begin  The News International
  3. Life Biosciences secures $80 million Series D financing  The Pharma Letter
  4. Life Biosciences lands $80m to push cell reset therapy  Longevity.Technology
  5. Life Biosciences Raises $80M in Series D Funding  FinSMEs

Want the full story? Read the original reporting

Read on Endpoints News